Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Legend Biotech Corp maintains a gross margin of 57.66%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -15.96%, while the net margin is -14.57%. These profitability ratios, combined with a Return on Equity (ROE) of -22.53%, provide a clear picture of how effectively LEGN converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, LEGN competes directly with industry leaders such as XENE and CNTA. With a market capitalization of $3.30B, it holds a significant position in the sector. When comparing efficiency, LEGN's gross margin of 57.66% stands against XENE's 100.00% and CNTA's 100.00%. Such benchmarking helps identify whether Legend Biotech Corp is trading at a premium or discount relative to its financial performance.
